company background image
OCC

OrthocellASX:OCC Stock Report

Market Cap

AU$101.5m

7D

-0.9%

1Y

39.5%

Updated

18 Oct, 2021

Data

Company Financials
OCC fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

OCC Overview

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally.

Price History & Performance

Summary of all time highs, changes and price drops for Orthocell
Historical stock prices
Current Share PriceAU$0.53
52 Week HighAU$0.32
52 Week LowAU$0.66
Beta0.039
1 Month Change7.07%
3 Month Change0%
1 Year Change39.47%
3 Year Change125.53%
5 Year Change11.58%
Change since IPO47.22%

Recent News & Updates

Shareholder Returns

OCCAU BiotechsAU Market
7D-0.9%2.3%0.9%
1Y39.5%1.5%20.2%

Return vs Industry: OCC exceeded the Australian Biotechs industry which returned 1.5% over the past year.

Return vs Market: OCC exceeded the Australian Market which returned 20.2% over the past year.

Price Volatility

Is OCC's price volatile compared to industry and market?
OCC volatility
OCC Beta0.039
Industry Beta1.61
Market Beta1

Stable Share Price: OCC is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: OCC's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006n/aPaul Andersonhttps://www.orthocell.com.au

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia and internationally. The company’s principal products include CelGro, a naturally derived collagen medical device for use in multiple indications to augment the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle.

Orthocell Fundamentals Summary

How do Orthocell's earnings and revenue compare to its market cap?
OCC fundamental statistics
Market CapAU$101.51m
Earnings (TTM)-AU$9.04m
Revenue (TTM)AU$1.02m

99.8x

P/S Ratio

-11.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
OCC income statement (TTM)
RevenueAU$1.02m
Cost of RevenueAU$625.65k
Gross ProfitAU$392.32k
ExpensesAU$9.43m
Earnings-AU$9.04m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.047
Gross Margin38.54%
Net Profit Margin-887.76%
Debt/Equity Ratio0%

How did OCC perform over the long term?

See historical performance and comparison

Valuation

Is Orthocell undervalued compared to its fair value and its price relative to the market?

6.02x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate OCC's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate OCC's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: OCC is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: OCC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate OCC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: OCC is overvalued based on its PB Ratio (6x) compared to the AU Biotechs industry average (4.9x).


Future Growth

How is Orthocell forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.5%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orthocell has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Orthocell performed over the past 5 years?

-18.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: OCC is currently unprofitable.

Growing Profit Margin: OCC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: OCC is unprofitable, and losses have increased over the past 5 years at a rate of 18.5% per year.

Accelerating Growth: Unable to compare OCC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OCC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).


Return on Equity

High ROE: OCC has a negative Return on Equity (-53.55%), as it is currently unprofitable.


Financial Health

How is Orthocell's financial position?


Financial Position Analysis

Short Term Liabilities: OCC's short term assets (A$17.1M) exceed its short term liabilities (A$1.9M).

Long Term Liabilities: OCC's short term assets (A$17.1M) exceed its long term liabilities (A$522.4K).


Debt to Equity History and Analysis

Debt Level: OCC is debt free.

Reducing Debt: OCC has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: OCC has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: OCC has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 8.7% each year


Dividend

What is Orthocell current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate OCC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate OCC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if OCC's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if OCC's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of OCC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.1yrs

Average management tenure


CEO

Paul Anderson (55 yo)

no data

Tenure

AU$1,334,226

Compensation

Mr. Paul Frederick Anderson serves as Chief Executive Officer of Orthocell Limited. Mr. Anderson has been Managing Director and Executive Director of Orthocell Limited since March 21, 2006. Mr. Anderson ha...


CEO Compensation Analysis

Compensation vs Market: Paul's total compensation ($USD990.30K) is above average for companies of similar size in the Australian market ($USD302.72K).

Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: OCC's management team is seasoned and experienced (5.1 years average tenure).


Board Members

Experienced Board: OCC's board of directors are considered experienced (8.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: OCC insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.6%.


Top Shareholders

Company Information

Orthocell Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Orthocell Limited
  • Ticker: OCC
  • Exchange: ASX
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$101.508m
  • Shares outstanding: 191.52m
  • Website: https://www.orthocell.com.au

Location

  • Orthocell Limited
  • Building 191
  • Murdoch University
  • Murdoch
  • Western Australia
  • 6150
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/18 15:30
End of Day Share Price2021/10/18 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.